S&P 500   3,333.69 (-0.80%)
DOW   27,686.91 (-0.38%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   3,333.69 (-0.80%)
DOW   27,686.91 (-0.38%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   3,333.69 (-0.80%)
DOW   27,686.91 (-0.38%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   3,333.69 (-0.80%)
DOW   27,686.91 (-0.38%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
Log in

NASDAQ:CRBPCorbus Pharmaceuticals News Headlines

$6.96
+0.09 (+1.31 %)
(As of 08/11/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.72
Now: $6.96
$7.53
50-Day Range
$6.27
MA: $7.28
$8.39
52-Week Range
$3.29
Now: $6.96
$8.78
Volume2.57 million shs
Average Volume1.25 million shs
Market Capitalization$568.72 million
P/E RatioN/A
Dividend YieldN/A
Beta1.33

Headlines

Corbus Pharmaceuticals (NASDAQ CRBP) News Headlines

Source:
DateHeadline
Corbus Pharmaceuticals (NASDAQ:CRBP) Rating Lowered to Sell at Zacks Investment ResearchCorbus Pharmaceuticals (NASDAQ:CRBP) Rating Lowered to Sell at Zacks Investment Research
marketbeat.com - August 7 at 9:43 PM
Corbus Pharmaceuticals (NASDAQ:CRBP) Posts Quarterly  Earnings Results, Misses Expectations By $0.13 EPSCorbus Pharmaceuticals (NASDAQ:CRBP) Posts Quarterly Earnings Results, Misses Expectations By $0.13 EPS
americanbankingnews.com - August 9 at 4:17 PM
Corbus Pharmaceuticals (CRBP) "Buy" Rating Reiterated at HC WainwrightCorbus Pharmaceuticals' (CRBP) "Buy" Rating Reiterated at HC Wainwright
americanbankingnews.com - August 8 at 12:22 AM
Corbus Pharmaceuticals (NASDAQ:CRBP) Trading Down 11.5%Corbus Pharmaceuticals (NASDAQ:CRBP) Trading Down 11.5%
americanbankingnews.com - August 6 at 8:58 PM
Corbus Pharmaceuticals Holdings, Inc. (CRBP) CEO Yuval Cohen on Q2 2020 Results - Earnings Call TranscriptCorbus Pharmaceuticals Holdings, Inc. (CRBP) CEO Yuval Cohen on Q2 2020 Results - Earnings Call Transcript
seekingalpha.com - August 6 at 3:02 PM
Corbus Pharmaceuticals EPS misses by $0.14, misses on revenueCorbus Pharmaceuticals EPS misses by $0.14, misses on revenue
seekingalpha.com - August 6 at 10:00 AM
Corbus Pharmaceuticals Reports Second Quarter Financial Results and Corporate UpdatesCorbus Pharmaceuticals Reports Second Quarter Financial Results and Corporate Updates
finance.yahoo.com - August 6 at 10:00 AM
Corbus Pharmaceuticals Completes Enrollment in DETERMINE Phase 3 Study of Lenabasum for Treatment of DermatomyositisCorbus Pharmaceuticals Completes Enrollment in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
finance.yahoo.com - August 5 at 1:50 PM
 Brokerages Expect Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Will Post Quarterly Sales of $3.90 Million Brokerages Expect Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Will Post Quarterly Sales of $3.90 Million
americanbankingnews.com - August 5 at 1:40 AM
Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Given Consensus Recommendation of "Buy" by AnalystsCorbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Given Consensus Recommendation of "Buy" by Analysts
americanbankingnews.com - August 4 at 2:12 AM
Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price Up 8.3%Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price Up 8.3%
americanbankingnews.com - August 3 at 8:08 PM
Zacks: Brokerages Anticipate Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Will Announce Earnings of -$0.38 Per ShareZacks: Brokerages Anticipate Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Will Announce Earnings of -$0.38 Per Share
americanbankingnews.com - August 3 at 6:14 PM
Corbus Pharmaceuticals (CRBP) Scheduled to Post Earnings on ThursdayCorbus Pharmaceuticals (CRBP) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - August 1 at 10:06 PM
Corbus Pharmaceuticals to Report Second Quarter Results on August 6, 2020Corbus Pharmaceuticals to Report Second Quarter Results on August 6, 2020
finance.yahoo.com - July 30 at 12:49 PM
Corbus Pharmaceuticals (NASDAQ:CRBP) Trading Down 6.3%Corbus Pharmaceuticals (NASDAQ:CRBP) Trading Down 6.3%
www.americanbankingnews.com - July 29 at 9:22 PM
Corbus Pharmaceuticals secures debt funding of $50MCorbus Pharmaceuticals secures debt funding of $50M
seekingalpha.com - July 29 at 9:58 AM
Corbus Pharmaceuticals Strengthens Balance Sheet with up to $121 Million in New CapitalCorbus Pharmaceuticals Strengthens Balance Sheet with up to $121 Million in New Capital
finance.yahoo.com - July 29 at 9:58 AM
Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target Increased to $18.00 by Analysts at Jefferies Financial GroupCorbus Pharmaceuticals (NASDAQ:CRBP) Price Target Increased to $18.00 by Analysts at Jefferies Financial Group
www.americanbankingnews.com - July 27 at 11:59 AM
CRBP Dec 2020 15.000 callCRBP Dec 2020 15.000 call
uk.finance.yahoo.com - July 26 at 1:57 PM
CRBP Nov 2020 3.000 callCRBP Nov 2020 3.000 call
uk.finance.yahoo.com - July 26 at 1:57 PM
After 6 Years Corbus Shareholders Face The Ultimate Milestone: The Imminent Release Of Lenabasums Phase 3 DataAfter 6 Years Corbus Shareholders Face The Ultimate Milestone: The Imminent Release Of Lenabasum's Phase 3 Data
seekingalpha.com - July 22 at 6:50 AM
What Does Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) CEO Pay Reveal?What Does Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) CEO Pay Reveal?
finance.yahoo.com - July 15 at 5:55 PM
What Does Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) CEO Pay Reveal?What Does Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) CEO Pay Reveal?
finance.yahoo.com - July 15 at 5:55 PM
Corbus Pharmaceuticals Holdings Inc (CRBP): Are Hedge Funds Right About This Stock?Corbus Pharmaceuticals Holdings Inc (CRBP): Are Hedge Funds Right About This Stock?
finance.yahoo.com - July 5 at 10:59 PM
CRBP Corbus Pharmaceuticals Holdings, Inc. Common StockCRBP Corbus Pharmaceuticals Holdings, Inc. Common Stock
www.nasdaq.com - July 5 at 12:22 AM
Corbus nearing finish line in lenabasum study in cystic fibrosisCorbus nearing finish line in lenabasum study in cystic fibrosis
seekingalpha.com - June 22 at 2:29 PM
Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic FibrosisCorbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
finance.yahoo.com - June 22 at 9:28 AM
Corbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics in the Journal of Cystic FibrosisCorbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics in the Journal of Cystic Fibrosis
finance.yahoo.com - June 1 at 1:00 PM
Is Corbus Pharmaceuticals (CRBP) Stock a Solid Choice Right Now?Is Corbus Pharmaceuticals (CRBP) Stock a Solid Choice Right Now?
finance.yahoo.com - June 1 at 1:00 PM
Will Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Spend Its Cash Wisely?Will Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Spend Its Cash Wisely?
finance.yahoo.com - May 28 at 8:28 AM
Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic SclerosisCorbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
finance.yahoo.com - May 27 at 12:06 PM
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-CongressCorbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress
finance.yahoo.com - May 22 at 12:23 PM
Edited Transcript of CRBP earnings conference call or presentation 11-May-20 12:30pm GMTEdited Transcript of CRBP earnings conference call or presentation 11-May-20 12:30pm GMT
finance.yahoo.com - May 17 at 11:52 PM
Corbus Pharmaceuticals (CRBP) Moves to Buy: Rationale Behind the UpgradeCorbus Pharmaceuticals (CRBP) Moves to Buy: Rationale Behind the Upgrade
finance.yahoo.com - May 15 at 2:14 PM
Corbus Pharmaceuticals to Present at Two Upcoming Investor ConferencesCorbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
finance.yahoo.com - May 15 at 9:13 AM
Do Options Traders Know Something About Corbus Pharmaceuticals (CRBP) Stock We Don't?Do Options Traders Know Something About Corbus Pharmaceuticals (CRBP) Stock We Don't?
finance.yahoo.com - May 14 at 7:02 PM
Do Options Traders Know Something About Corbus Pharmaceuticals (CRBP) Stock We Dont?Do Options Traders Know Something About Corbus Pharmaceuticals (CRBP) Stock We Don't?
www.nasdaq.com - May 14 at 2:01 PM
Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Tops Revenue EstimatesCorbus Pharmaceuticals (CRBP) Reports Q1 Loss, Tops Revenue Estimates
finance.yahoo.com - May 11 at 5:17 PM
Corbus Pharmaceuticals EPS misses by $0.02, misses on revenueCorbus Pharmaceuticals EPS misses by $0.02, misses on revenue
seekingalpha.com - May 11 at 7:47 AM
Corbus Pharmaceuticals Reports First Quarter Financial Results and Corporate UpdatesCorbus Pharmaceuticals Reports First Quarter Financial Results and Corporate Updates
finance.yahoo.com - May 11 at 7:47 AM
Corbus announces open market sale agreement with JefferiesCorbus announces open market sale agreement with Jefferies
seekingalpha.com - May 4 at 4:17 PM
Corbus Pharmaceuticals to Report First Quarter Results on May 11, 2020Corbus Pharmaceuticals to Report First Quarter Results on May 11, 2020
finance.yahoo.com - May 4 at 8:42 AM
Viela Bio Announces Election of Rachelle Jacques to its Board of DirectorsViela Bio Announces Election of Rachelle Jacques to its Board of Directors
finance.yahoo.com - April 30 at 4:44 PM
Corbus Announces Publication of Lenabasum Systemic Sclerosis Double-Blind, Placebo-Control Phase 2 Clinical Trial Results in Arthritis & RheumatologyCorbus Announces Publication of Lenabasum Systemic Sclerosis Double-Blind, Placebo-Control Phase 2 Clinical Trial Results in Arthritis & Rheumatology
finance.yahoo.com - April 29 at 11:55 AM
Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Shareholders Booked A 86% Gain In The Last Five YearsCorbus Pharmaceuticals Holdings (NASDAQ:CRBP) Shareholders Booked A 86% Gain In The Last Five Years
finance.yahoo.com - April 28 at 10:48 AM
3 Reasons Medical Marijuana Is a Better Long-Term Investment Than Recreational Pot3 Reasons Medical Marijuana Is a Better Long-Term Investment Than Recreational Pot
www.fool.com - April 19 at 7:51 AM
Implied Volatility Surging for Corbus (CRBP) Stock OptionsImplied Volatility Surging for Corbus (CRBP) Stock Options
finance.yahoo.com - April 2 at 10:53 AM
Edited Transcript of CRBP earnings conference call or presentation 12-Mar-20 12:30pm GMTEdited Transcript of CRBP earnings conference call or presentation 12-Mar-20 12:30pm GMT
finance.yahoo.com - March 31 at 10:01 PM
RBC sees 21% upside in Danaher in premarket analyst actionRBC sees 21% upside in Danaher in premarket analyst action
seekingalpha.com - March 26 at 7:57 AM
Corbus Pharmaceuticals Holdings, Inc. Just Reported Earnings, And Analysts Cut Their Target PriceCorbus Pharmaceuticals Holdings, Inc. Just Reported Earnings, And Analysts Cut Their Target Price
finance.yahoo.com - March 14 at 12:35 PM
Corbus Pharma down 9% premarket on Q4 missCorbus Pharma down 9% premarket on Q4 miss
seekingalpha.com - March 12 at 2:35 PM
This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.